Celeste, M.G. et al. 2017. Budget impact analysis of dabigatran compared with rivaroxaban in the prevention of the thromboembolic risk in patients with non-valvular atrial fibrillation. Farmeconomia. Health economics and therapeutic pathways. 18, 1 (Nov. 2017). DOI:https://doi.org/10.7175/fe.v18i1.1327.